Antibiotic treatment of CF lung disease: From bench to bedside

被引：20
作者：
Bals, Robert [1 ]
Hubert, Dominique [2 ]
Tuemmler, Burkhard [3 ]
机构：
[1] Univ Klinikum Saarlandes, Klin Med 5, D-66421 Homburg, Germany
[2] Hop Cochin, Assistance Publ Hop Paris, Serv Pneumol, CRCM, F-75679 Paris 14, France
[3] Hannover Med Sch, Klin Forschergrp, Abt Padiatr Pneumol & Neonatol, D-30625 Hannover, Germany
来源：
JOURNAL OF CYSTIC FIBROSIS | 2011年 / 10卷
关键词：
Antimicrobial treatment; Drug development; Microbiome; Susceptibility testing; CYSTIC-FIBROSIS PATIENTS; PSEUDOMONAS-AERUGINOSA; INNATE IMMUNITY; INHALATION; INFECTION; SPUTUM; PHARMACOKINETICS; MICROBIOLOGY; PATHOGENS; BIOFILMS;
D O I：
10.1016/S1569-1993(11)60019-2
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Chronic infection of the respiratory tract is a hallmark of cystic fibrosis (CF). Antibiotic treatment has been used as one of the mainstays of therapy and together with other treatment modalities has resulted in increased survival of CF patients. Increasing resistance of CF-specific pathogens to various classes of antibiotics explains the need for novel antibiotic strategies. This review focuses on the future development of new antibiotic therapies, including: (I) New targets, (2) novel antibiotic regimens in CF, (3) new antibiotics, and (4) other investigational therapies. In addition, we briefly summarize developments in the area of microbial diagnostics and discuss interactions between the complex pulmonary microflora. (C) 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码：S146 / S151
页数：6
相关论文
共 51 条
  • [1] Activity and Interactions of Liposomal Antibiotics in Presence of Polyanions and Sputum of Patients with Cystic Fibrosis
    Alipour, Misagh
    Suntres, Zacharias E.
    Halwani, Majed
    Azghani, Ali O.
    Omri, Abdelwahab
    [J]. PLOS ONE, 2009, 4 (05):
  • [2] Robust Salmonella metabolism limits possibilities for new antimicrobials
    Becker, D
    Selbach, M
    Rollenhagen, C
    Ballmaier, M
    Meyer, TF
    Mann, M
    Bumann, D
    [J]. NATURE, 2006, 440 (7082) : 303 - 307
  • [3] Beringer P, 2001, Curr Opin Pulm Med, V7, P434, DOI 10.1097/00063198-200111000-00013
  • [4] The thymidine-dependent small-colony-variant phenotype is associated with hyermutability and antibiotic resistance in clinical Staphylococcus aureus isolates
    Besier, Silke
    Zander, Johannes
    Kahl, Barbara C.
    Kraiczy, Peter
    Brade, Volker
    Wichelhaus, Thomas A.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (06) : 2183 - 2189
  • [5] Molecular Detection of Multiple Emerging Pathogens in Sputa from Cystic Fibrosis Patients
    Bittar, Fadi
    Richet, Herve
    Dubus, Jean-Christophe
    Reynaud-Gaubert, Martine
    Stremler, Nathalie
    Sarles, Jacques
    Raoult, Didier
    Rolain, Jean-Marc
    [J]. PLOS ONE, 2008, 3 (08):
  • [6] Quorum-sensing blockade as a strategy for enhancing host defences against bacterial pathogens
    Bjarnsholt, Thomas
    Givskov, Michael
    [J]. PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES, 2007, 362 (1483) : 1213 - 1222
  • [7] Pseudomonas aeruginosa Biofilms in the Respiratory Tract of Cystic Fibrosis Patients
    Bjarnsholt, Thomas
    Jensen, Peter Ostrup
    Fiandaca, Mark J.
    Pedersen, Jette
    Hansen, Christine Ronne
    Andersen, Claus Bogelund
    Pressler, Tacjana
    Givskov, Michael
    Hoiby, Niels
    [J]. PEDIATRIC PULMONOLOGY, 2009, 44 (06) : 547 - 558
  • [8] Has nature already identified all useful antibacterial targets?
    Bumann, Dirk
    [J]. CURRENT OPINION IN MICROBIOLOGY, 2008, 11 (05) : 387 - 392
  • [9] CARRUTHERS J, 1975, BRIT J PREV SOC MED, V29, P239
  • [10] The Calgary Biofilm Device: New technology for rapid determination of antibiotic susceptibilities of bacterial biofilms
    Ceri, H
    Olson, ME
    Stremick, C
    Read, RR
    Morck, D
    Buret, A
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (06) : 1771 - 1776
123456